VAERS Explorer
Back to explore

Report #2875835

Received Dec 1, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
1 yrs
State
MD
Recovered
Unknown
Vaccinated
Nov 24, 2025
Onset
Nov 24, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
TYPTYPHOID VI POLYSACCHARIDE (TYPHIM VI)SANOFI PASTEUR1Y2A031MOT / LL

Symptoms (2)

No adverse eventProduct administered to patient of inappropriate age

Symptom narrative

the early administration of TYPHIM VI to a patient under 2 years of age with no reported adverse event; Initial information received on 24-Nov-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 1 years old male patient who had early administration of Typhoid Vi Polysaccharide Vaccine [Typhim Vi], with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Yellow fever vaccine live (17D-204) (Yf-vax) for Immunisation. On 24-Jun-2024 at 10:45 hours, the patient received 0.5mL (dose 1) of suspect Typhoid Vi Polysaccharide Vaccine, Solution for injection (lot Y2A031M, expiry date 30-Jun-2027, frequency once and strength standard) via intramuscular route in the left thigh for Immunization and the early administration of typhim vi to a patient under 2 years of age with no reported adverse event (product administered to patient of inappropriate age) (latency same day). It was reported ‘registered nurse (RN) called to seek guidance following the early administration of Typhim VI to a patient under 2 years of age. They also asked about potential side effects that might arise following the vaccination. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Other medications

Yf-vax